Laura Lee Sandler
Known title: Chief Operating OfficerCIK: 0002075401
Associated companies
Transaction History
| ORKA | ▼ Sell | Open Market | 906 | $87K | 9/15/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 5,000 | $39K | 9/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 1,000 | $91K | 9/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 4,000 | $368K | 9/1/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 5,000 | $39K | 7/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,237 | $210K | 7/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,263 | $214K | 7/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 500 | $48K | 7/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 600 | $42K | 6/15/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 5,000 | $39K | 5/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,200 | $138K | 5/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 1,800 | $115K | 5/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 400 | $26K | 5/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 200 | $13K | 5/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 100 | $7K | 5/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 300 | $20K | 5/1/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 600 | $25K | 3/16/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 5,000 | $39K | 3/2/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,325 | $77K | 3/2/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 2,675 | $90K | 3/2/2026 | View on chart |
| ORKA | ▲ Buy | Grant | 32,500 | $0 | 1/23/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 5,000 | $39K | 1/2/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 8,748 | $246K | 1/2/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 3,144 | $91K | 1/2/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 1,108 | $33K | 1/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.